DOI · e01.org

Low Pretreatment Albumin-to-Globulin Ratios Predict Poor Survival Outcomes in Patients with Head and Neck Cancer: A Systematic Review and Meta-analysis

Yunting Wang, Liang‐Tseng Kuo, Chia‐Hsuan Lai, Yuan‐Hsiung Tsai, Yi‐Chan Lee, Cheng‐Ming Hsu, Chun‐Ta Liao, Chung‐Jan Kang, Ethan I. Huang, Ming‐Shao Tsai, Geng‐He Chang, Yao-Te Tsai · Journal of Cancer · 2023

  • DOI 10.7150/jca.80955
  • Publisher Ivyspring International Publisher
  • Type review
  • Issued 2023

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · review · 2023

Abstract

Background: Studies have indicated that a low albumin-to-globulin ratio (AGR) before treatment is linked to poor prognosis of many cancers, but the prognostic impact of AGR remains controversial in head and neck cancer (HNC).This meta-analysis examined the prognostic value of AGR in HNC.Methods: We systematically searched the Embase, PubMed, and Cochrane library for relevant articles from inception to July 22, 2022.Studies conducted from 2000 to 2022 exploring the prognostic value of AGR in HNC were retrieved.We employed a random-effects model and calculated pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) to examine the associations of AGR with survival outcome.Results: Our analysis included nine studies involving 3211 patients with HNC.The pooled results revealed significant associations between low pretreatment AGRs and poor disease-free survival (HR = 1.97, 95% CI 1.58-2.45,p < 0.001), distant metastasis-free survival (HR = 1.64, 95% CI 1.25-2.16,p < 0.001), overall survival (HR = 2.18, 95% CI 1.65-2.88,p < 0.001), T3-T4 status (OR = 2.22, 95% CI 1.43-3.44,p < 0.001), stage III-IV disease (OR = 2.62, 95% CI 1.62-4.23,p < 0.001), and lymph node metastasis (OR = 1.95, 95% CI 1.29-2.82,p = 0.001) in patients with HNC.Conclusion: AGR can serve as a prognostic biomarker in managing HNC, and a low pretreatment AGR is strongly associated with adverse survival outcomes and advanced cancer status.Additional large-scale prospective trials must be conducted to assess the validity of our findings.

Open the resolved locator · 10.7150/jca.80955

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:21 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v14p0281.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.